The journey leading to breakthroughs is never downhill, rather challenging, insidious even.
We partake in it, like nobody else does.
We don’t conceal it.
We celebrate it.
This is out path.
Alongside it we thrive.
We’re a community of people of science, belonging to different companies, yet walking towards the same north star. We beat the path end-to-end, from discovery to development bringing together our legacy and expertise.
Here in Nerviano, where life-changing molecules are born.
Chairman, NMS Group
Andrea Agazzi has over 25 years of experience in financial transactions in the pharmaceutical sector, securitization of healthcare receivables and Revenue-based Financing, debt restructuring, mergers and acquisitions. After working in international investment banks, for over 10 years he was General Manager of a factoring company active mainly in the healthcare sector and at the same time, he sits on the Boards of Directors of pharmaceutical companies and manufacturers of medical devices in Italy and the USA. Graduated in Political Economy, Master of Finance, he is co-author of books on budget analysis and studies on company valuation.
CEO, NMS Group
Nanding Zhao, PhD and MBA, is an industry veteran across drug discovery and development, with a proven track record of leading multi-disciplinary teams and multinational projects with his in-depth knowledge and broad experiences, supporting robust pipelines. Prior to joining NMS Group, he was the deputy general manager of Hefei Sari Oborgen Biopharma, and CEO of Kanova Biopharmaceutical Co. Ltd., overseeing the development and implementation of global strategic plans and ensuring seamless coordination of business operations of the companies. Prior to that, he was Head of external innovation of China Novartis Institutes for Biomedical Research co., Ltd. (Cnibr) and associate director of External Research of oncology pcu at Eisai, Inc. USA, leading and managing anti-inflammatory and anticancer drug discovery projects, collaborating with partners from China, US, Europe and Japan in both positions. He holds a Doctor of Philosophy degree in Molecular Biology and Medicine from the University of Kyushu in Kyushu, Japan.
Chairperson, Nerviano Medical Sciences
Barbara Marenco has over 25 years of experience in the Administration, Finance and Control area, of which more than half was dedicated to keep NMS group a solid and sound presence. As CFO, she oversees the administrative and financial activities and management control of the holding and its subsidiaries. She holds a degree in Economics and Commerce from the University of Turin.
CEO, Nerviano Medical Sciences
Guoxian Wu, PhD, has over 20 years of biotech/pharmaceutical R&D experience with proven track record. He is co-founder of Lyrea Therapeutics and Xian-Feng Pharmaceuticals, Inc. He has an extensive experience in leading internal programs and managing CROs worldwide, effective communication skills, good people skills and strong team building skills. He demonstrates leadership and management capabilities in leading drug discovery and development from initiation to clinical trials.
VP, Nerviano Medical Sciences
Frank Gan, PharmD, has over 25 years of preclinical and clinical research experience in both academia and the biopharmaceutical industry. Leveraging his experiences in both clinical research and early drug discovery, he has developed clinical research strategies, spearheaded the global clinical research programs in metabolic disease and oncology, and played a pivotal role for the successful launch of several drug products while working at Merck, BMS, Eli Lilly, and Janssen. Currently, he leads and supervises the development and execution of the global regulatory and clinical development strategies for Nerviano Medical Sciences S.r.l.
Chairman and CEO, NerPharMA
Angelo Colombo has more than thirty years of experience in the pharmaceutical field, gained both in the context of multinationals such as Pfizer, Schering-Plough, Pharmacia, and in important CDMOs like Corden Pharma. He is the Chairman and CEO of Nerpharma. He holds a degree in Chemistry and Pharmaceutical Technologies obtained at the University of Milan.
Enrico Pesenti, along his career, with over 20 years of experience in Oncology Drug Discovery and Preclinical Research with Farmitalia Carlo Erba, Pharmacia, Pfizer, Nerviano Medical Sciences and Accelera, has acquired a solid knowledge in pharmacology, cell biology, experimental therapeutics and imaging applied both to industrial and academic research, and a successful track record of drug discovery and preclinical development of targeted cancer therapies. He holds a degree in Veterinary Medicine from the University of Milano.